Allurion Smart Capsule Delivers 20% Weight Loss in 36 Weeks

Case-controlled study in 1,143 patients demonstrates superior weight reduction, fat mass loss, and visceral fat loss with the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone

Average weight reduction of 20% at 36 weeks, on par with bariatric surgery and high-dose GLP-1 therapy

Improved body composition without adversely affecting muscle mass

NATICK, Mass.–(BUSINESS WIRE)–
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of a peer-reviewed, case-controlled study on the use of the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone and its impact on weight loss and body composition.

Published in Obesity Surgery, a leading international journal dedicated to the treatment of obesity and metabolic disease, results from the study demonstrate a significantly higher weight reduction, fat mass loss, and visceral fat loss in patients treated with the Allurion Smart Capsule combined with lifestyle intervention compared to those receiving lifestyle intervention alone. At 36 weeks, Allurion Smart Capsule patients had an average weight reduction of 20% with favorable body composition changes.

The study included 1,143 patients with a body mass index (BMI) of ≥ 30 kg/m².

“This study underscores the synergistic effects of the Allurion Smart Capsule with an individualized lifestyle intervention, with average weight reduction of 20% and nearly twice as much fat reduction at 36 weeks without adverse effects on muscle mass,” said Dr. Yannis Raftopoulos, Director of the Weight Management Program at Holyoke Medical Center and Principal Investigator. “This study demonstrated a safety profile better than bariatric surgery and GLP-1 therapy and an efficacy comparable to bariatric surgery and better than real-world, high-dose GLP-1 therapy at a substantially lower cost. This approach has the potential to set a new benchmark in obesity management not only by achieving significant weight loss but also by improving body composition—something not previously reported.”

The publication of this peer-reviewed study further bolsters an extensive data set on the safety and efficacy of the Allurion Smart Capsule.

“With over 30 peer-reviewed publications on the Allurion Smart Capsule, we believe there is little doubt that it has a unique value proposition for patients with obesity,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “This publication demonstrates that using an individualized lifestyle intervention program in conjunction with the Allurion Smart Capsule can lead to significant weight loss with clear improvements in body composition, something patients who undergo bariatric surgery or high-dose GLP-1 therapy struggle to achieve.”

The Allurion Smart Capsule is designed to be swallowed during a brief outpatient visit, filled once in the stomach, and pass naturally after four months. When combined with Allurion’s Virtual Care Suite, patients also receive digital support and remote monitoring aimed to change behaviors and improve outcomes.

About Allurion

Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Smart Capsule, the world’s first and only swallowable, Procedureless™ gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Smart Capsule is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Forward-Looking Statements

This press release contains forward-looking statements that reflect Allurion’s beliefs and assumptions based on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terms, although not all forward-looking statements contain these words. Although Allurion believes it has a reasonable basis for each forward-looking statement contained in this release, these statements involve risks and uncertainties that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

Forward-looking statements in this press release include, but are not limited to, statements regarding: establishing a new standard for weight loss; pioneering in metabolically healthy weight loss; combining the Allurion capsule with lifestyle modification causing enhanced weight loss and body composition results with a better safety profile than other weight loss therapies; and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to management.

Allurion cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward looking statements are subject to a number of risks and uncertainties, including, among others, general economic, political and business conditions; the ability of Allurion to obtain and maintain regulatory approval for, and successfully commercialize, the Allurion Program, including the Allurion Balloon; the timing of, and results from, Allurion’s clinical studies and trials, including with respect to the combination of GLP-1s with the Allurion Balloon; the evolution of the markets in which Allurion competes, including the impact of GLP-1 drugs; the ability of Allurion to maintain its listing on the New York Stock Exchange; a changing regulatory landscape in the highly competitive industry in which Allurion competes; the impact of the imposition of current and potential tariffs and trade negotiations, and those factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 27, 2025, and as amended on August 19, 2025, and updated from time to time by its other filings with the SEC, and its Quarterly Report on Form 10-Q filed with the SEC on November 17, 2025. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Allurion undertakes no obligation to update any forward-looking statements to reflect any new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events, other than as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251120543799/en/

Media

Tara North, Woodrow Communications

Email: t.north@woodrowcommunications.com

Phone: +447912103070

Investor

investors@allurion.com

Source: Allurion Technologies, Inc.